2025 07 11 Recent Veterinary Drug Approval Updates Graphic

Recent Veterinary Drug Approval Updates: What Pharmacists Should Know

For ACVP Members and Veterinary Pharmacy Professionals
Two recent FDA actions bring noteworthy changes to veterinary pharmacotherapy—particularly for pharmacists involved in compounding and those managing inventory of critical-use medications in clinical settings.

________________________________________
Felicyn-CA1 (sirolimus) – Conditional Approval for Management of Ventricular Hypertrophy in Cats

The FDA has granted conditional approval to Felicyn-CA1, (sirolimus delayed-release tablets) for the management of ventricular hypertrophy in cats with subclinical hypertrophic cardiomyopathy (HCM). Developed by TriviumVet, this product represents the first targeted therapeutic option for this condition in feline patients.

While the approval is conditional—meaning that ongoing data collection is required to demonstrate full effectiveness—the product has already met the FDA’s standards for reasonable expectation of efficacy and demonstrated safety in cats. The availability of a commercial product is a critical step forward for feline cardiology.

Implications for Pharmacists:

  • Stop compounding sirolimus for feline HCM: With the approval of Felicyn-CA1, compounded sirolimus should no longer be used for this indication unless the commercial product is unavailable or medically inappropriate for a specific patient.
  • Education opportunity: Veterinary pharmacists may be called upon to educate veterinarians and clients on proper use, potential side effects, and drug handling of this novel immunosuppressant-based therapy.
  • Felycin-CA1 is only available by prescription from a licensed veterinarian. Felycin-CA1 is given to cats at a target dose of 0.3 mg/kg orally once weekly. Cats should be screened for pre-existing liver disease before starting Felycin-CA1, and it should not be used in cats with pre-existing liver disease or diabetes mellitus.

________________________________________
PropofolVet Multidose (ANADA 200-793) – First Generic Multidose Propofol Injectable Emulsion for Dogs

The FDA has also approved PropofolVet Multidose under ANADA 200-793, marking the first generic version of the 28-day in-use multidose formulation of propofol for dogs. This approval provides an equivalent and cost-effective alternative to the pioneer product, making it easier for practices to maintain on-hand anesthesia options.

Key Points for Pharmacists:

  • Same in-use period: Like the reference product, PropofolVet Multidose remains stable for up to 28 days after first puncture when properly stored and handled.
  • Sterility and inventory monitoring: Pharmacy teams should ensure compliance with in-use dating and aseptic handling, and communicate clearly with veterinary staff regarding vial tracking and expiration once opened.

________________________________________

Final Thoughts

These approvals underscore the continued advancement of species-specific, FDA-reviewed therapeutics, and the essential role that veterinary pharmacists play in guiding ethical dispensing, regulatory compliance, and safe medication use.

As always, ACVP encourages its members to stay current on FDA announcements and practice evidence-based, compliant veterinary pharmacy.